Cellectis (NASDAQ:CLLS) Stock Price Passes Above Fifty Day Moving Average - Should You Sell?

Key Points

• Cellectis S.A. shares recently crossed above their 50-day moving average of $2.25, reaching a high of $2.68 during trading.
• Analysts have cut the target price for Cellectis from $5.00 to $4.00, with a current average rating of "Buy" and a consensus price target at $4.00.
• The company reported a quarterly loss with an earnings per share (EPS) of ($0.24), missing estimates, despite generating revenue of $18.19 million which surpassed expectations.

Cellectis S.A. (NASDAQ:CLLS - Get Free Report) passed above its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $2.25 and traded as high as $2.68. Cellectis shares last traded at $2.57, with a volume of 35,096 shares.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Barclays lowered their price target on Cellectis from $5.00 to $4.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Wall Street Zen downgraded Cellectis from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, Cellectis has a consensus rating of "Buy" and an average target price of $4.00.

Cellectis Price Performance

The company has a quick ratio of 1.38, a current ratio of 1.38 and a debt-to-equity ratio of 0.58. The stock has a market capitalization of $143.96 million, a PE ratio of -3.16 and a beta of 3.03. The company has a 50-day moving average of $2.29 and a 200 day moving average of $1.71.

Cellectis (NASDAQ:CLLS - Get Free Report) last released its quarterly earnings data on Monday, August 4th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.09). The company had revenue of $18.19 million for the quarter, compared to analyst estimates of $10.07 million. Cellectis had a negative return on equity of 68.05% and a negative net margin of 100.69%. Sell-side analysts predict that Cellectis S.A. will post -0.46 EPS for the current year.

Hedge Funds Weigh In On Cellectis

Several hedge funds have recently bought and sold shares of the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in Cellectis by 228.4% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,722,664 shares of the biotechnology company's stock worth $5,856,000 after acquiring an additional 3,284,409 shares in the last quarter. Long Focus Capital Management LLC increased its holdings in shares of Cellectis by 2.2% in the 1st quarter. Long Focus Capital Management LLC now owns 4,717,293 shares of the biotechnology company's stock valued at $5,849,000 after acquiring an additional 100,000 shares during the last quarter. Millennium Management LLC purchased a new position in Cellectis during the 4th quarter worth approximately $962,000. Acadian Asset Management LLC grew its stake in Cellectis by 132.9% during the 1st quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company's stock worth $55,000 after buying an additional 26,461 shares during the last quarter. Finally, OLD Mission Capital LLC purchased a new position in Cellectis during the 1st quarter worth approximately $31,000. Institutional investors and hedge funds own 63.90% of the company's stock.

About Cellectis

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.